Fremanezumab
- Generic Name
- Fremanezumab
- Brand Names
- Ajovy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1655501-53-3
- Unique Ingredient Identifier
- PF8K38CG54
- Background
Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist ubro...
- Indication
Fremanezumab is indicated for the preventative treatment of migraine in adults.
- Associated Conditions
- Migraine
- Associated Therapies
- -
A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT04447729
Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT04334408
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 353
- Registration Number
- NCT04041284
- Locations
- π©πͺ
Teva Investigational Site 32734, Leipzig, Germany
π¬π·Teva Investigational Site 63075, Athens, Greece
πΊπΈTeva Investigational Site 14337, San Diego, California, United States
A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 189
- Registration Number
- NCT03965091
- Locations
- πΊπΈ
Teva Investigational Site 14179, Dallas, Texas, United States
πΊπΈTeva Investigational Site 14431, Mesa, Arizona, United States
πΊπΈTeva Investigational Site 14164, San Diego, California, United States
Fremanezumab Compassionate Use Program for Pediatric Patients
- Conditions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT03539393
A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT03347188
- Locations
- πΊπΈ
Teva Investigational Site 14119, Albany, New York, United States
πΊπΈTeva Investigational Site 14055, Dallas, Texas, United States
πΊπΈTeva Investigational Site 14064, Philadelphia, Pennsylvania, United States
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 838
- Registration Number
- NCT03308968
- Locations
- πΊπΈ
Teva Investigational Site 14760, Decatur, Georgia, United States
πΊπΈTeva Investigational Site 14739, San Diego, California, United States
πΈπͺTeva Investigational Site 42054, Stockholm, Sweden
A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 275
- Registration Number
- NCT03107052
- Locations
- πΊπΈ
Teva Investigational Site 13812, Stamford, Connecticut, United States
πΊπΈTeva Investigational Site 13809, Raleigh, North Carolina, United States
πΊπΈTeva Investigational Site 13824, Philadelphia, Pennsylvania, United States
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 259
- Registration Number
- NCT02964338
- Locations
- πΊπΈ
Teva Investigational Site 13813, Englewood, Colorado, United States
πΊπΈTeva Investigational Site 13820, Princeton, New Jersey, United States
πΊπΈTeva Investigational Site 13824, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT02945046
- Locations
- πΊπΈ
Teva Investigational Site 13834, Phoenix, Arizona, United States
πΊπΈTeva Investigational Site 13819, Canoga Park, California, United States
πΊπΈTeva Investigational Site 13811, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.